lasofoxifene has been researched along with Hormone-Dependent Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arriola, MW; Brown, TA; Cameron, KO; Cole, MJ; Crawford, DT; Da Silva Jardine, P; Ebbinghaus, CF; Elliott, NC; Gauthier, JW; Ke, HZ; Newhouse, BN; Nickerson, DF; Pan, LC; Pirie, CM; Qi, H; Reinhold, AR; Rosati, RL; Simmons, HA; Sweetnam, PM; Thompson, DD; Tjoa, CM; Tkalcevic, GT; Toler, SM | 1 |
| Gutgesell, LM; Karumudi, B; Lee, S; Lu, Y; Thatcher, GR; Tonetti, DA; Wang, Y; Xiong, R; Zhao, H; Zhao, J | 1 |
2 other study(ies) available for lasofoxifene and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene.
Topics: Administration, Oral; Animals; Biological Availability; Bone Density; Breast Neoplasms; Cell Division; Cholesterol; Estrogen Antagonists; Ethinyl Estradiol; Female; Humans; Hypolipidemic Agents; Neoplasms, Hormone-Dependent; Organ Size; Ovariectomy; Pyrrolidines; Rats; Receptors, Estrogen; Tetrahydronaphthalenes; Tumor Cells, Cultured; Uterus | 1998 |
Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Mice, Nude; Models, Molecular; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Thiophenes | 2017 |